Windward Bio’s WIN378 Delivers Positive Phase 2 Asthma Data as Twice-Yearly Anti-TSLP Antibody Moves Into Phase 3
Windward Bio has reported positive interim Phase 2 results for WIN378, also known as HBM9378 or SKB378, showing sustained improvements in lung function and key inflammatory biomarkers after a single dose in patients with uncontrolled asthma. With a…
Clover Biopharma’s RSV-hMPV-PIV3 Combination Vaccines Deliver Encouraging Phase 2 Results in Older Adults
Clover Biopharmaceuticals has reported positive preliminary Phase 2 data for SCB-1022 and SCB-1033, two next-generation combination respiratory vaccines designed to protect older adults against multiple major respiratory viruses with a single shot. The…
Kelun-Biotech’s TROP2 ADC Sac-TMT Shows Durable Activity Across Genomically Altered NSCLC in a Phase 2 Study
Sichuan Kelun-Biotech has reported new Phase 2 data for its TROP2-directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT; SKB264/MK-2870) in heavily pretreated non-small cell lung cancer (NSCLC), showing durable antitumor activity across…
Keymed completed Phase 2 trial of CM512, a TSLP x IL-13 bispecific antibody for chronic sinusitis
The Phase II clinical trial of long-acting TSLP x IL-13 bispecific antibody CM512 for the treatment of chronic sinusitis with nasal polyps (CRSwNP) has met all study endpoints.